Type 2 Diabetes

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!

A pair of studies published within days of one another provide insight into the apparent increase in risk of type 1 diabetes diagnoses following COVID-19, but one study purports this increase may not be the result of COVID-19.

Released on September 23, the consensus report from the American Diabetes Association and European Association for the Study of Diabetes outlines optimal strategies for management of hyperglycemia in type 2 diabetes—their first update on the subject since 2019.

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

Results of the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study provide insight into the comparative effectiveness of DPP-4 inhibitors, GLP-1 RAs, sulfonylureas, and insulin glargine for glycemic control and cardiovascular outcomes in people with type 2 diabetes.

LX9211 is a potent, orally delivered, selective small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

Results of a modeling study provide insight into the projected prevalence of type 1 diabetes in 2040 as well as offering an overview of the estimates of the current undiagnosed cases, current life expectancy differences based on location, and risk of death for undiagnosed patients.

Announced on September 20, the alerts from the FDA and Medtronic notify users of a potential cybersecurity risk identified through internal testing at Medtronic that would allow unauthorized users to the pump's communication protocol, which could allow unauthorized boluses.

An analysis of nearly 15 years of follow-up data from 97 patients who underwent bariatric surgery during adolescence provides insight into the benefits of surgery on weight loss and comorbidities among those with severe obesity.

Lifestyle interventions increased weight-specific quality of life in Latino youth with diabetes compared with usual care.

An analysis of data from patient surveys provides insight into patient preferences related to oral therapies for type 2 diabetes, with blinded results indicating a preference for SGLT2 inhibitors over oral GLP-1 RA or DPP-4 inhibitors.

People with diabetes in Italy and the UK reported the highest rates of anxiety at 63% and 51%, respectively.

An analysis of data from SURPASS-2 and -3 provides evidence demonstrating the reduction in time to achieve glycemic targets and weight loss with use of tirzepatide compared with semaglutide 1.0 mg and long-acting insulin degludec.

An analysis of data from more than 100,000 hospitalizations for hypoglycemia and hyperglycemic emergencies provides insight into the purported increase in risk for these events observed with extreme heat.

Short-term treatment with rosuvastatin was not linked to changes in insulin resistance markers in a cohort of children with familial hypercholesterolemia.

Released on September 13, the US Preventive Services Task Force concluded there was a lack of sufficient evidence related to the benefits and harms of screening in their first-ever recommendation statement on screening for type 2 diabetes and prediabetes in children with no known history or symptoms of either disease.

Results of the TARGET trial provide insight into the effects of tight glycemic targets versus less tight targets on maternal and perinatal outcomes among women with gestational diabetes.

Black/African American individuals are more likely to have an amputation within the first year following DFU, while women appeared to have a greater likelihood of delayed amputation.

Results of the CREATE trial published in NEJM suggest the use of open-source automated insulin delivery systems was associated with improved time in target glucose range compared with sensor-augmented pump therapy in children and adults with type 1 diabetes.

On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.

An analysis of patient data from the DCCT and EDIC studies details differences in the cardiometabolic risk factor profiles and management approaches for women and men with type 1 diabetes.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES shares clinical pearls for the management of school aged children with diabetes.

An expert in diabetes education provides an overview of dosing requirements and appropriate administration requirements necessary for the administration of hypoglycemia rescue therapies.

A study presented at EASD 22 comparing 600k patients with type 2 diabetes against 1.2 million controls suggests a diagnosis of T2D prior to turning 40 was associated with a more than 5-fold increase in risk of mortality, heart failure hospitalization, and coronary heart disease.

Lower prescriptions for racial, ethnic groups relative to White, non-Hispanic patients remained after accounting for patient- and system-level characteristics.